A Phase II, Randomised, Double-Blind, Placebo Controlled, Parallel-Group, Multicentre, Three Month Duration Potassium Reduction Initiative to Optimize RAAS Inhibition Therapy With Sodium Zirconium Cyclosilicate in Heart Failure
Phase of Trial: Phase II
Latest Information Update: 24 Jan 2019
At a glance
- Drugs Zirconium silicate (Primary)
- Indications Hyperkalaemia
- Focus Therapeutic Use
- Acronyms PRIORITIZE HF
- Sponsors AstraZeneca
- 07 Aug 2018 Status changed from not yet recruiting to recruiting.
- 26 Jun 2018 Planned End Date changed from 16 Aug 2019 to 4 Sep 2019.
- 26 Jun 2018 Planned primary completion date changed from 16 Aug 2019 to 4 Sep 2019.